Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer

Next Previous
Trial Profile

An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Folitixorin (Primary) ; Pemetrexed
  • Indications Rectal cancer
  • Focus Adverse reactions
  • Acronyms LARS-2
  • Sponsors Isofol Medical

Most Recent Events

  • 04 Feb 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
  • 10 Sep 2013 Planned End Date changed from 1 Jul 2013 to 1 Sep 2014 as reported by ClinicalTrials.gov.
  • 04 May 2013 Planned number of patients changed from 52 to 70 as reported by European Clinical Trials Database.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top